Genetron Health to Release Thirteen Research Findings at 21st World Conference on Lung Cancer
Exploring the characteristics of gene mutation
Seven studies (#1766, #2150, #2226, #2007, #1780, #1452, #835) on EGFR mutations, JAK family gene mutations, FGFR1-4 mutations, KIT activating mutations, mTOR signaling pathway mutations, and IDH1/2 mutations, respectively, were conducted to explore their mutation patterns and distribution characteristics in Chinese lung cancer patients, and to search for drug-resistant targets and effective solutions.
Exploring the characteristics of gene fusion
Study 3609 involved an in-depth analysis of 10 gene fusion patterns and distributions in the Chinese lung cancer population, as well as their co-occurrences with other driver mutations, in order to construct initial gene fusion mapping. Study 3601 focused on the prevalence and clinical benefit ratio of NTRK1 rare fusion in the Chinese lung cancer population.
Detecting immunotherapy markers
Study 3698 demonstrated the usage of KMT2C/D gene mutations as a positive predictor of the efficacy of non-small cell lung cancer (NSCLC) immunotherapy, indicating that patients with such gene mutations may benefit from immunotherapy. Study 3713 focused on the differences amongst DDR (DNA Damage Response) signaling pathway-related gene mutations in NSCLC and small cell lung cancer (SCLC), supporting the research of immunotherapy in the two patient groups.
Optimizing bioinformatics models
Based on six CpG sites, Study 2231 developed a random forest classification model, a new type of bioinformatics model, to distinguish early lung adenocarcinoma from benign nodules.
Rare case research
Study 3630 used
“The thirteen research findings we are releasing at the WCLC, which focus on the characteristics of the Chinese lung cancer population, have made discoveries in multiple dimensions and demonstrated Genetron Health’s strong capabilities in the fundamental research of lung cancer genomics,” said Dr.
ABSTRACT NUMBER |
ABSTRACT TITLE |
2226 |
Identification of FGFR Mutations in Chinese Lung Cancer Patients by Next-Generation Sequencing |
3609 |
Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis |
2150 |
Next generation sequencing reveals the genetic landscape of JAK family in Chinese lung cancer patients |
1766 |
Comprehensive investigation of uncommon EGFR mutations in 14,429 Chinese lung cancer patients |
1780 |
Next-generation sequencing guided the gene mutations associated with mTOR-inhibitors in Chinese lung cancer patients |
3601 |
The prevalence of NTRK1 fusion in a Chinese lung cancer cohort |
3630 |
A recommended one-step targeted sequencing technology for identification of a dual CD74-ROS1 in NSCLC |
2231 |
Identification of DNA methylation markers to distinguish early-stage lung adenocarcinomas from benign pulmonary nodules |
3713 |
DNA damage response gene alterations and their association with tumor mutation burden and response to immunotherapy in NSCLC and SCLC |
3698 |
|
2007 |
Molecular Alterations of KIT Oncogene in a Large Cohort of Chinese Pan-Lung Cancer Patients |
835 |
Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC |
1452 |
A |
About
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding research results, genomics exploration, bioinformatics model construction and optimization, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are made under the “safe harbor” provisions of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005381/en/
Media Relations
yanrong.zhao@genetronhealth.com
ICR
Edmond.Lococo@icrinc.com
Mobile: +86 138-1079-1408
genetron.pr@icrinc.com
Source: